Skip to main content
. Author manuscript; available in PMC: 2025 Apr 28.
Published in final edited form as: Nat Immunol. 2024 Jan 10;25(3):562–575. doi: 10.1038/s41590-023-01721-9

Extended Data Fig. 6. NP-Ficoll does not produce GCBC-derived MBCs.

Extended Data Fig. 6.

a, Number of total MBCs at Day 5 (left) and Day 28 (right) between NP-CGG + PBS (day 5; n=4, day 28, n= 5), NP-Ficoll + PBS (day 5; n=6, day 28, n= 4), and NP-Ficoll + GK1.5 (day 5; n=5, day 28, n= 7) treated mice from Fig. 5. b, Left/middle: Representative flow plots of pre-gated NIP+ B cells from Day 5 post-immunization for NP-KLH + PBS, NP-Ficoll + PBS, NP-KLH + GK1.5, and NP-Ficoll + GK1.5 treated GCET-TamCre+/−R26-LSL-YFP+/− mice. Mice were given one dose of tamoxifen on Day 3; right: Representative flow plots of pre-gated NIP+ B cells from Day 28 post-immunization for NP-KLH + PBS, NP-Ficoll + PBS, NP-KLH + GK1.5, and NP-Ficoll + GK1.5 treated GCET-TamCre+/−R26-LSL-YFP+/− mice. Mice were given one dose of tamoxifen every other day from day 3–13. c, Number of YFP+ GCBCs (NIP+CD19+CD138−CD38−GL7+) per spleen at day 5 (n=3 per group). d, left: Percent YFP+ of DP MBCs (NIP+CD19+CD138−CD38+GL7−), middle: Number of total DP MBCs per spleen, and right: Number of YFP+ DPs per spleen at day 28 (n=3 per group). Bars display mean ± s.d. P-values were calculated using two-tailed Welch’s t-test (*P<=0.05, **P<0.01, ***P<0.001). Actual p-values are listed in source data.